ResMed to Acquire Noctrix Health for $340M to Expand into Restless Legs Syndrome

San Diego, CA, April 30, 2026 (Globe Newswire) -- ResMed (NYSE: RMD) signed a definitive agreement to acquire Noctrix Health for $340 million, adding the company's FDA de novo-classified Nidra device to its sleep health portfolio. Nidra is a noninvasive nerve stimulation device for moderate-to-severe restless legs syndrome, the world's third most prevalent sleep disorder, affecting approximately 17 million people in the U.S. ResMed said Noctrix's revenue growth rate and gross margin both exceed its core business, and that Noctrix prescriptions flow through the same sleep physician and HME/DME channel where ResMed holds leading market share. The transaction is expected to close on or around June 1, 2026.

Read full article here.